COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

In-Home Evaluation of Episodic Administration of Palovarotene in Fibrodysplasia Ossificans Progressiva (FOP) Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02521792
Recruitment Status : Terminated (Subjects were enrolled into a different Phase 2 study (PVO-1A-202, NCT02279095).)
First Posted : August 13, 2015
Last Update Posted : May 1, 2020
Information provided by (Responsible Party):
Ipsen ( Clementia Pharmaceuticals Inc. )